Acarbose and Octreotide Acetate: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 10, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Acarbose
Octreotide Acetate
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
You've been given two medicines that can both affect your blood sugar: acarbose, which slows how fast your body absorbs sugar from food, and octreotide, which changes how much insulin and glucagon your body releases. Because octreotide affects those blood-sugar hormones, your glucose can swing in either direction, meaning you could see low blood sugar (shaky, sweaty, dizzy) or higher-than-usual readings.
The good news is this is very manageable. Your care team can check your blood sugar more often when octreotide is started or changed, and adjust your diabetes medicines as needed. Please keep taking both as prescribed and let your pharmacist or doctor know how your readings look.
Effect: Increased risk of dysglycemia (both hypoglycemia and hyperglycemia) when acarbose is combined with octreotide.
Mechanism: Octreotide, a somatostatin analog, suppresses secretion of insulin and glucagon, altering glucose homeostasis and the response to antidiabetic therapy. Neither agent is enzymatically dependent in this interaction; the effect is pharmacodynamic.
- Direction: Unpredictable glucose regulation; severe hyperglycemia or hypoglycemia possible.
- Onset: Unspecified.
- Evidence: Theoretical.
- Management: Optimize glycemic control before initiating octreotide; anticipate antidiabetic dose adjustment and intensify glucose monitoring around initiation or dose changes.
What happens
An increased risk of hypoglycemia and impaired glucose regulation
Interaction Deep Dive
Analogs of somatostatin suppress the release of both insulin and glucagon3. This can lead to pronounced elevations in blood glucose. In patients whose diabetes is poorly controlled, antidiabetic therapy should be optimized before the somatostatin analog is initiated 4. It may be necessary to modify the dose of the antidiabetic drug and to monitor glucose more frequently 125.
Why it happens (mechanism)
Altered glucose metabolism
How to manage this interaction
This combination can be handled well with a few practical steps your care team may take:
- Getting your diabetes well-controlled before octreotide is started, if possible.
- Checking your blood sugar more often, especially when octreotide is begun or its dose changes.
- Adjusting your acarbose or other diabetes medicines. The right dose may need to be individualized by your care team based on your readings.
What you can do: Keep taking both medicines as prescribed, monitor your glucose as directed, and report any lows (shaky, sweaty, confused) or persistent highs to your pharmacist or doctor.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Acarbose and Octreotide Acetate together?
Combining acarbose and octreotide can make blood sugar harder to predict, so expect more frequent glucose checks and possible dose adjustments from your care team. Keep taking both as prescribed and report any unusual highs or lows. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Acarbose and Octreotide Acetate interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Acarbose and Octreotide Acetate interaction managed?
This combination can be handled well with a few practical steps your care team may take: Getting your diabetes well-controlled before octreotide is started, if possible. Checking your blood sugar more often, especially when octreotide is begun or its dose changes. Adjusting your acarbose or other diabetes medicines. The right dose may need to be individualized by your care team based on your readi… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Acarbose or Octreotide Acetate need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (5)
- Product Information: TOUJEO(R) subcutaneous injection, insulin glargine subcutaneous injection. sanofi-aventis (per manufacturer), Bridgewater, NJ, 2015. DailyMed
- Product Information: Tresiba subcutaneous injection solution, insulin degludec subcutaneous injection solution. Novo Nordisk A/S (per EMA), Bagsvaerd, Denmark, 2013. DailyMed
- Product Information: Sandostatin(R) LAR Depot intramuscular injection suspension, octreotide acetate intramuscular injection suspension. Novartis Pharmaceuticals Corporation (per FDA), East Hanover, NJ, 2014.
- Product Information: SIGNIFOR(R) LAR intramuscular injection suspension, pasireotide intramuscular injection suspension. Novartis Pharmaceuticals Corporation (per FDA), East Hanover, NJ, 2014.
- Product Information: ADMELOG(R) subcutaneous, intravenous injection, insulin lispro subcutaneous, intravenous injection. sanofi-aventis US LLC (per DailyMed), Bridgewater, NJ, 2023. DailyMed
Keep reading about Acarbose
Keep reading about Octreotide Acetate
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist